Published in Cancer on June 15, 2008
Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA (2010) 5.78
Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis. Ann Intern Med (2013) 2.96
Targeted biopsy in the detection of prostate cancer using an office based magnetic resonance ultrasound fusion device. J Urol (2012) 2.89
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res (2013) 2.70
Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol (2010) 2.65
Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer. Urology (2014) 2.62
Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial. Eur Urol (2012) 2.62
Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH database. Urology (2010) 2.45
Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? Radiology (2010) 2.38
Active surveillance for prostate cancer compared with immediate treatment: an economic analysis. Cancer (2011) 2.36
Can Confirmatory Biopsy be Omitted in Patients with Prostate Cancer Favorable Diagnostic Features on Active Surveillance? J Urol (2015) 2.04
Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer. J Urol (2010) 1.91
Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort. J Clin Oncol (2009) 1.89
Performance characteristics of MR imaging in the evaluation of clinically low-risk prostate cancer: a prospective study. Radiology (2012) 1.74
The role of magnetic resonance imaging in delineating clinically significant prostate cancer. Urology (2014) 1.66
Magnetic resonance imaging for predicting prostate biopsy findings in patients considered for active surveillance of clinically low risk prostate cancer. J Urol (2012) 1.64
Increased incidence of pathologically nonorgan confined prostate cancer in African-American men eligible for active surveillance. Urology (2013) 1.63
Quality of life in men undergoing active surveillance for localized prostate cancer. J Natl Cancer Inst Monogr (2012) 1.49
Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository. Urology (2009) 1.46
Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification. Eur Urol (2014) 1.42
Modeling grade progression in an active surveillance study. Stat Med (2013) 1.41
Active surveillance for the management of localized prostate cancer: Guideline recommendations. Can Urol Assoc J (2015) 1.38
Targeted prostate biopsy in select men for active surveillance: do the Epstein criteria still apply? J Urol (2014) 1.22
Prostate cancer managed with active surveillance: role of anatomic MR imaging and MR spectroscopic imaging. Radiology (2010) 1.18
Tumor focality in prostate cancer: implications for focal therapy. Nat Rev Clin Oncol (2010) 1.09
Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. J Urol (2015) 1.01
Treatment of localized prostate cancer: when is active surveillance appropriate? Nat Rev Clin Oncol (2010) 0.96
Is there an optimal management for localized prostate cancer? Clin Interv Aging (2010) 0.91
International multicentre study examining selection criteria for active surveillance in men undergoing radical prostatectomy. Br J Cancer (2012) 0.90
Initial experience with electronic tracking of specific tumor sites in men undergoing active surveillance of prostate cancer. Urol Oncol (2014) 0.88
Management of low risk prostate cancer-active surveillance and focal therapy. Nat Rev Clin Oncol (2014) 0.88
Active surveillance in Canadian men with low-grade prostate cancer. CMAJ (2016) 0.86
Prostate cancer: a review of active surveillance. Res Rep Urol (2014) 0.86
The Quantitative Criteria Based on the Fractal Dimensions, Entropy, and Lacunarity for the Spatial Distribution of Cancer Cell Nuclei Enable Identification of Low or High Aggressive Prostate Carcinomas. Front Physiol (2016) 0.86
Components of cell-matrix linkage as potential new markers for prostate cancer. Cancers (Basel) (2011) 0.85
Pathological findings following radical prostatectomy in patients who are candidates for active surveillance: impact of varying PSA levels. Asian J Androl (2011) 0.84
Prostate cancer: reducing overtreatment: active surveillance in low-risk disease. Nat Rev Urol (2011) 0.84
African American men with low-grade prostate cancer have increased disease recurrence after prostatectomy compared with Caucasian men. Urol Oncol (2014) 0.84
Role of active surveillance in the management of localized prostate cancer. J Natl Cancer Inst Monogr (2012) 0.83
Active surveillance and focal therapy for low-intermediate risk prostate cancer. Transl Androl Urol (2015) 0.82
Active surveillance as a practical strategy to differentiate lethal and non-lethal prostate cancer subtypes. Asian J Androl (2012) 0.82
Current status of active surveillance in prostate cancer. Investig Clin Urol (2016) 0.81
Current clinical challenges in prostate cancer. Transl Androl Urol (2013) 0.81
Active surveillance for prostate cancer. Int J Urol (2015) 0.80
Relationship between illness uncertainty, anxiety, fear of progression and quality of life in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int (2015) 0.80
Active surveillance for low-risk prostate cancer. F1000 Med Rep (2012) 0.80
A novel measure of dietary change in a prostate cancer dietary program incorporating mindfulness training. J Acad Nutr Diet (2012) 0.79
Active surveillance in men with low-risk prostate cancer: current and future challenges. Am J Clin Exp Urol (2013) 0.78
Should Gleason 6 be labeled as cancer? Curr Opin Urol (2015) 0.78
Active surveillance for favorable-risk prostate cancer: a short review. Korean J Urol (2010) 0.78
Impact of race on survival in patients with clinically nonmetastatic prostate cancer who deferred primary treatment. Cancer (2011) 0.78
Predictive role of free prostate-specific antigen in a prospective active surveillance program (PRIAS). World J Urol (2015) 0.77
Upgrading and upstaging of low-risk prostate cancer among Korean patients: a multicenter study. Asian J Androl (2015) 0.77
Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers. World J Urol (2015) 0.77
Biomarkers for prostate cancer: present challenges and future opportunities. Future Sci OA (2015) 0.77
Divorcing diagnosis from treatment: contemporary management of low-risk prostate cancer. Korean J Urol (2013) 0.76
Low serum testosterone predicts upgrading and upstaging of prostate cancer after radical prostatectomy. Asian J Androl (2016) 0.76
A randomized trial of diet in men with early stage prostate cancer on active surveillance: rationale and design of the Men's Eating and Living (MEAL) Study (CALGB 70807 [Alliance]). Contemp Clin Trials (2014) 0.75
Advances and future directions in management of prostate cancer. Indian J Surg (2010) 0.75
Active surveillance of prostate cancer: a questionnaire survey of urologists, clinical oncologists and urology nurse specialists across three cancer networks in the United Kingdom. BMC Urol (2015) 0.75
Active surveillance for prostate cancer: when to recommend delayed intervention. Asian J Androl (2015) 0.75
The Influence of Psychosocial Constructs on the Adherence to Active Surveillance for Localized Prostate Cancer in a Prospective, Population-based Cohort. Urology (2017) 0.75
Biopsy Perineural Invasion in Prostate Cancer Patients Who are Candidates for Active Surveillance by Strict and Expanded Criteria. Urology (2016) 0.75
Using Electronic Health Record Data to Identify Prostate Cancer Patients That May Qualify for Active Surveillance. EGEMS (Wash DC) (2016) 0.75
Active surveillance for intermediate-risk prostate cancer. Prostate Cancer Prostatic Dis (2016) 0.75
Imaging and Markers as Novel Diagnostic Tools in Detecting Insignificant Prostate Cancer: A Critical Overview. Int Sch Res Notices (2014) 0.75
The importance of active surveillance, and immediate re-biopsy in low-risk prostate cancer: The largest series from Turkey. Turk J Urol (2016) 0.75
The uptake of active surveillance for the management of prostate cancer: A population-based analysis. Can Urol Assoc J (2016) 0.75
Pathologic Outcomes in Men with Low-risk Prostate Cancer Who Are Potential Candidates for Contemporary, Active Surveillance Protocols. J Korean Med Sci (2015) 0.75
Analysis of different tumor volume thresholds of insignificant prostate cancer and their implications for active surveillance patient selection and monitoring. Prostate Int (2014) 0.75
Should patients consider active surveillance? Cancer (2008) 0.75
Limiting overdiagnosis of low-risk prostate cancer through an evaluation of the predictive value of transrectal and power Doppler ultrasonography. J Ultrasound (2016) 0.75
Active Holistic Surveillance: The Nutritional Aspect of Delayed Intervention in Prostate Cancer. J Nutr Metab (2016) 0.75
The detection and upgrade rates of prostate adenocarcinoma following transperineal template-guided prostate biopsy - a tertiary referral centre experience. Cent European J Urol (2016) 0.75
Association between number of prostate biopsies and patient-reported functional outcomes after radical prostatectomy: implications for active surveillance protocols. BJU Int (2015) 0.75
Variation in Guideline Concordant Active Surveillance Followup in Diverse Urology Practices. J Urol (2016) 0.75
Investigation of risk factors for prostate cancer patients with bone metastasis based on clinical data. Exp Ther Med (2010) 0.75
Outcome of repeated prostatic biopsy during active surveillance: implications for focal therapy. World J Urol (2014) 0.75
Pathological outcomes of Japanese men eligible for active surveillance after radical prostatectomy. Int J Clin Oncol (2013) 0.75
Active surveillance for low-risk prostate cancer in Austria: the online registry of the Qualitätspartnerschaft Urologie (QuapU). Wien Klin Wochenschr (2016) 0.75
An assessment of Prostate Cancer Research International: Active Surveillance (PRIAS) criteria for active surveillance of clinically low-risk prostate cancer patients. Can Urol Assoc J (2017) 0.75
Trends in active surveillance for very low-risk prostate cancer: do guidelines influence modern practice? Cancer Med (2017) 0.75
Communicating risk in active surveillance of localised prostate cancer: a protocol for a qualitative study. BMJ Open (2017) 0.75
Differences in practice patterns between urologists and radiation oncologists in the management of localized prostate cancer: a cross-sectional survey. World J Urol (2015) 0.75
Early detection of prostate cancer: AUA Guideline. J Urol (2013) 9.14
Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol (2010) 8.93
PSA screening among elderly men with limited life expectancies. JAMA (2006) 5.70
Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst (2007) 5.69
Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer (2010) 5.22
The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol (2004) 5.09
Saw palmetto for benign prostatic hyperplasia. N Engl J Med (2006) 4.99
National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst (2003) 4.81
Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol (2007) 4.56
Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst (2003) 4.42
Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol (2012) 4.24
Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol (2013) 4.04
Prediction of erectile function following treatment for prostate cancer. JAMA (2011) 3.92
The changing face of prostate cancer. J Clin Oncol (2005) 3.84
Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol (2003) 3.62
Increased telomerase activity and comprehensive lifestyle changes: a pilot study. Lancet Oncol (2008) 3.57
Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy. Eur Urol (2012) 3.26
Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA (2007) 3.25
Active surveillance for early-stage prostate cancer: review of the current literature. Cancer (2008) 3.18
Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer (2008) 3.14
Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes? Am J Surg Pathol (2012) 3.05
Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol (2003) 2.93
Active surveillance for prostate cancer: progress and promise. J Clin Oncol (2011) 2.93
Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol (2010) 2.89
Factors associated with satisfaction with prostate cancer care: results from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). BJU Int (2012) 2.88
Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy. Eur Urol (2009) 2.88
Best practice statement on cryosurgery for the treatment of localized prostate cancer. J Urol (2008) 2.85
Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst (2009) 2.84
Best practices in robot-assisted radical prostatectomy: recommendations of the Pasadena Consensus Panel. Eur Urol (2012) 2.84
Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer (2008) 2.83
Population-based comparative effectiveness of nephron-sparing surgery vs ablation for small renal masses. BJU Int (2012) 2.81
The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer (2011) 2.78
Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol (2003) 2.77
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res (2013) 2.70
Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol (2007) 2.69
Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol (2010) 2.65
Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. J Clin Oncol (2005) 2.57
Androgen deprivation therapy and cardiovascular risk. J Clin Oncol (2011) 2.55
Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol (2012) 2.55
High prevalence of screening-detected prostate cancer among Afro-Caribbeans: the Tobago Prostate Cancer Survey. Cancer Epidemiol Biomarkers Prev (2002) 2.46
Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol (2013) 2.46
Prostate cancer, version 2.2014. J Natl Compr Canc Netw (2014) 2.40
Prepubertal orchiopexy for cryptorchidism may be associated with lower risk of testicular cancer. J Urol (2007) 2.39
Pathological outcomes of candidates for active surveillance of prostate cancer. J Urol (2009) 2.39
Target localization and real-time tracking using the Calypso 4D localization system in patients with localized prostate cancer. Int J Radiat Oncol Biol Phys (2006) 2.33
NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw (2010) 2.31
Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. J Urol (2006) 2.31
The contemporary concept of significant versus insignificant prostate cancer. Eur Urol (2011) 2.29
Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database. J Urol (2009) 2.23
Freedom from a detectable ultrasensitive prostate-specific antigen at two years after radical prostatectomy predicts a favorable clinical outcome: analysis of the SEARCH database. Urology (2009) 2.23
A simple schema for informed decision making about prostate cancer screening. Ann Intern Med (2014) 2.12
Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Oncol (2011) 2.08
Prostate cancer early detection. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2007) 2.06
Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol (2005) 2.05
Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy. Magn Reson Med (2006) 2.04
Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer (2006) 2.04
Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst (2005) 2.03
Imaging of retained surgical sponges in the abdomen and pelvis. AJR Am J Roentgenol (2003) 2.02
What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database. J Urol (2008) 2.02
Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol (2007) 2.01
Increased risk of high-grade prostate cancer among infertile men. Cancer (2010) 2.00
Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. AJR Am J Roentgenol (2004) 1.98
Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer (2006) 1.97
Race, biochemical disease recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database. Cancer (2007) 1.96
Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE. J Urol (2003) 1.93
Too frail for surgery? Initial results of a large multidisciplinary prospective study examining preoperative variables predictive of poor surgical outcomes. J Am Coll Surg (2013) 1.91
The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J Urol (2007) 1.91
Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. Urology (2002) 1.90